AZN.L - AstraZeneca PLC

LSE - LSE Delayed price. Currency in GBp
5,037.65
+57.15 (+1.15%)
As of 11:01AM GMT. Market open.
Stock chart is not supported by your current browser
Previous close4,980.50
Open5,000.00
Bid5,037.00 x 6100
Ask5,038.00 x 13000
Day's range4,984.50 - 5,041.00
52-week range4,136.50 - 5,520.00
Volume877,868
Avg. volume2,113,301
Market cap63.776B
Beta0.63
PE ratio (TTM)18.06
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield2.79 (4.51%)
Ex-dividend date2017-08-10
1y target estN/A
  • Reuters - UK Focus1 hour ago

    LIVE MARKETS-Euro zone stocks look past FX strength, hitting 10-year high

    Welcome to the home for real time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Danilo Masoni. Reach him on Messenger to share your thoughts on market ...

  • Reuters - UK Focus1 hour ago

    LIVE MARKETS-Semis: in chip shape

    Welcome to the home for real time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Danilo Masoni. Reach him on Messenger to share your thoughts on market ...

  • Reuters - UK Focus2 hours ago

    LIVE MARKETS-Further euro strength could dent earnings, says Deutsche

    Welcome to the home for real time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Danilo Masoni. Reach him on Messenger to share your thoughts on market ...

  • Reuters - UK Focus3 hours ago

    LIVE MARKETS-Opening snapshot: European shares nudge higher, profit warnings dominate UK stocks

    Welcome to the home for real time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Danilo Masoni. Reach him on Messenger to share your thoughts on market ...

  • Reuters - UK Focus3 hours ago

    LIVE MARKETS-What you need to know

    Welcome to the home for real time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Danilo Masoni. Reach him on Messenger to share your thoughts on market ...

  • Reuters - UK Focus4 hours ago

    LIVE MARKETS-Overnight headlines

    Welcome to the home for real time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Danilo Masoni. Reach him on Messenger to share your thoughts on market ...

  • Reuters11 hours ago

    At AstraZeneca, fewer drug projects bring big productivity jump

    A focus on fewer diseases, together with cuts in laboratories and staff, has delivered a more than fourfold increase in research productivity at drugmaker AstraZeneca (AZN.L), based on one key measure of success. The analysis published on Friday comes at a time of soul-searching among large pharmaceutical companies as they compete with smaller biotech firms, which are getting new drugs to market more efficiently. The turnaround evident this decade at AstraZeneca follows a shrinking of its global research and development organisation and a revision of R&D strategy in 2011, a year before the arrival of current chief executive Pascal Soriot.

  • Reuters11 hours ago

    At AstraZeneca, fewer drug projects bring big productivity jump

    A focus on fewer diseases, together with cuts in laboratories and staff, has delivered a more than fourfold increase in research productivity at drugmaker AstraZeneca (AZN.L), based on one key measure of success. The analysis published on Friday comes at a time of soul-searching among large pharmaceutical companies as they compete with smaller biotech firms, which are getting new drugs to market more efficiently. The turnaround evident this decade at AstraZeneca follows a shrinking of its global research and development organization and a revision of R&D strategy in 2011, a year before the arrival of current chief executive Pascal Soriot.

  • Why This Biotech Stock Could Outperform Expectations In Lung Cancer
    Investor's Business Daily14 hours ago

    Why This Biotech Stock Could Outperform Expectations In Lung Cancer

    AstraZeneca could bring in $3.8 billion in peak sales of immuno-oncology drug Imfinzi, an analyst said Thursday.

  • Reuters - UK Focus3 days ago

    Positive Keytruda lung cancer data sends Merck shares up 6 pct

    Positive lung cancer results for Merck (Jakarta: 28586808.JK - news) & Co Inc's blockbuster drug Keytruda assuaged investor concerns about delays in testing and the withdrawal of an application for European use of the drug, sending the drugmaker's shares up more than 6 percent. A cocktail of immunotherapy Keytruda and two chemotherapy medicines helped lung cancer patients live longer and stopped the disease from advancing, early results from a study showed, Merck said.

  • Globe Newswire3 days ago

    Cambrex & AstraZeneca Hold Ceremony to Mark Long-Term Supply Agreement at Karlskoga, Sweden Facility

    Cambrex Corporation (NYSE:CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today held an opening ceremony with AstraZeneca, at its Karlskoga, Sweden site to mark the commencement of a long-term manufacturing agreement between the two companies for a key intermediate. The announcement follows the completion, in 2017, of both a large-scale, multi-purpose capacity expansion which also includes hydrogenation capabilities and a dedicated continuous flow production unit capable of producing multiple metric tons of high purity advanced intermediates per annum at the Karlskoga facility.

  • AstraZeneca's Lynparza Label Now Includes Breast Cancer
    Zacks4 days ago

    AstraZeneca's Lynparza Label Now Includes Breast Cancer

    AstraZeneca (AZN) and Merck (MRK) announce approval of label expansion of ovarian cancer drug, Lynparza, to include HER2-/HR+ breast cancer with germline BRCA-mutation.

  • Foreign Stock Roundup: Infosys Beats; AstraZeneca's Asthma Drug Gets Approval in EU
    Zacks4 days ago

    Foreign Stock Roundup: Infosys Beats; AstraZeneca's Asthma Drug Gets Approval in EU

    Global markets endured a volatile week, guided by opposing factors.

  • US OKs 1st drug aimed at women with inherited breast cancer
    Associated Press7 days ago

    US OKs 1st drug aimed at women with inherited breast cancer

    U.S. regulators have approved the first drug aimed at women with advanced breast cancer caused by an inherited flawed gene.

  • Reuters7 days ago

    U.S. FDA approves expanded use of AstraZeneca cancer drug

    The drug belongs to a class of drug known as PARP inhibitors that has already been used to treat advanced BRCA-mutated ovarian cancer, the FDA said. This is the first time a PARP inhibitor has been approved to treat breast cancer and the first time any drug has been approved to treat certain patients with metastatic breast cancer associated with the same genetic mutation.

  • Globe Newswire7 days ago

    Myriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Lynparza™ (olaparib) In Patients with Metastatic Breast Cancer

    Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the U.S. Food and Drug Administration (FDA) approved BRACAnalysis CDx® for use as a companion diagnostic by healthcare professionals to identify patients with HER2-negative metastatic breast cancer who have a germline BRCA mutation and are candidates for treatment with the PARP inhibitor Lynparza (olaparib), marketed by AstraZeneca and Merck, known as MSD outside of the U.S. and Canada.  BRACAnalysis CDx is the first and only FDA-approved test for use in this indication.

  • Reuters - UK Focus7 days ago

    U.S. FDA approves expanded use of AstraZeneca cancer drug

    The U.S. Food and Drug Administration said on Friday it has approved expanded use of AstraZeneca Plc (NYSE: AZN - news) 's cancer drug Lynparza to include patients with metastatic breast cancer whose disease is associated with a mutation of the BRCA gene. The drug belongs to a class of drug known as PARP inhibitors that has already been used to treat advanced BRCA-mutated ovarian cancer, the FDA said. This is the first time a PARP inhibitor has been approved to treat breast cancer and the first time any drug has been approved to treat certain patients with metastatic breast cancer associated with the same genetic mutation.

  • AstraZeneca's Asthma Drug Benralizumab Gets Approval in EU
    Zacks8 days ago

    AstraZeneca's Asthma Drug Benralizumab Gets Approval in EU

    AstraZeneca's (AZN) benralizumab receives approval in Europe as maintenance treatment for severe eosinophilic asthma under the trade name Fasenra.

  • AstraZeneca plc isn’t the only high-growth stock I’d buy today
    Fool.co.uk10 days ago

    AstraZeneca plc isn’t the only high-growth stock I’d buy today

    This stock could deliver high returns alongside AstraZeneca plc (LON: AZN).

  • The Zacks Analyst Blog Highlights: Apple, Mastercard, 3M, AstraZeneca and Mondelez
    Zacks15 days ago

    The Zacks Analyst Blog Highlights: Apple, Mastercard, 3M, AstraZeneca and Mondelez

    The Zacks Analyst Blog Highlights: Apple, Mastercard, 3M, AstraZeneca and Mondelez

  • Globe Newswire16 days ago

    Myriad Genetics Announces Expanded Research Collaboration with AstraZeneca

    Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that AstraZeneca will use the Company’s myChoice® HRD Plus in an exploratory analysis to identify women with advanced ovarian cancer who may benefit from maintenance treatment with Lynparza (olaparib) and Avastin (bevacizumab).  Financial terms were not disclosed. Under the agreement, Myriad will use its myChoice HRD Plus test to evaluate patients enrolled in an ongoing Phase III trial.  In this collaboration, the companies will use the myChoice HRD Plus test to identify cases with homologous recombination deficiencies (HRD).

  • The Zacks Analyst Blog Highlights: Johnson and Johnson, AbbVie, Roche's, AstraZeneca and Novo-Nordisk A/S
    Zacks17 days ago

    The Zacks Analyst Blog Highlights: Johnson and Johnson, AbbVie, Roche's, AstraZeneca and Novo-Nordisk A/S

    The Zacks Analyst Blog Highlights: Johnson and Johnson, AbbVie, Roche's, AstraZeneca and Novo-Nordisk A/S

  • Reuters17 days ago

    New drug approvals hit 21-year high in 2017

    U.S. drug approvals hit a 21-year high in 2017, with 46 novel medicines winning a green light -- more than double the previous year -- while the figure also rose in the European Union. The EU recommended 92 new drugs including generics, up from 81, and China laid out plans to speed up approvals in what is now the world's second biggest market behind the United States.

  • Reuters - UK Focus17 days ago

    New drug approvals hit 21-year high in 2017

    U.S. drug approvals hit a 21-year high in 2017, with 46 novel medicines winning a green light -- more than double the previous year -- while the figure also rose in the European Union. The EU recommended 92 new drugs including generics, up from 81, and China laid out plans to speed up approvals in what is now the world's second biggest market behind the United States.

  • These 2 European Pharmas Grabbed Upgrades Ahead Of 2018 News
    Investor's Business Daily21 days ago

    These 2 European Pharmas Grabbed Upgrades Ahead Of 2018 News

    AstraZeneca and Novo Nordisk pulled upgrades on Friday as analysts looked ahead to key 2018 clinical trial readouts in ovarian cancer and diabetes.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes